Comparative Performance of Traditional and Novel Adiposity Indices for Predicting Insulin Resistance and Metabolic Syndrome in Chinese Women with Polycystic Ovary Syndrome

Why It Matters

Early identification of IR and MetS enables timely interventions that can curb diabetes and cardiovascular complications in a high‑risk PCOS population, informing clinical guidelines and routine screening practices.

Key Takeaways

• LAP and CVAI best predict insulin resistance (AUC≈0.81)
• CMI, LAP and VAI show highest MetS discrimination (AUC≥0.89)
• All indices strongly correlate with waist circumference and triglycerides
• Lower SHBG levels align with higher adiposity index scores
• Indices use routine labs, facilitating integration into electronic health records

Pulse Analysis

Polycystic ovary syndrome remains a leading cause of reproductive and metabolic dysfunction worldwide, with roughly half of affected women developing insulin resistance and a sizable minority progressing to metabolic syndrome. Traditional obesity measures such as BMI or waist‑to‑hip ratio capture overall mass but miss the nuanced interplay between visceral fat and lipid metabolism that drives these complications. Recent research has therefore turned to composite adiposity indices that blend anthropometry with biochemical markers, offering a more precise snapshot of metabolic health without costly imaging.

In a robust cohort of 944 Chinese women drawn from the PCOSAct trial, seven such indices were evaluated side‑by‑side. The lipid accumulation product (LAP) and Chinese visceral adiposity index (CVAI) emerged as the top predictors of insulin resistance, each delivering an area under the ROC curve around 0.81—significantly higher than traditional ratios. For metabolic syndrome, the cardiometabolic index (CMI) topped the chart with an AUC of 0.91, closely followed by LAP and VAI. These tools not only correlated strongly with waist circumference, triglycerides, and blood pressure but also reflected hormonal disturbances, showing inverse relationships with SHBG and positive ties to free androgen levels.

The practical implications are clear: clinicians can calculate LAP, CVAI or CMI using data already collected during routine visits—height, waist, fasting glucose, triglycerides, HDL‑C, and age. Embedding these formulas into electronic health records could trigger automated alerts for patients at heightened metabolic risk, prompting lifestyle counseling, early pharmacologic therapy, or specialist referral. While the study’s cross‑sectional design limits causal inference and its focus on Chinese women may affect generalizability, the findings provide a compelling case for revising PCOS screening protocols worldwide to incorporate these cost‑effective, evidence‑backed indices.